On May 7, 2025, Needham analyst Serge Belanger announced a revision in the price target for Cormedix (CRMD, Financial). The price target has been increased from $12.00 to $15.00, marking a substantial 25% rise. This adjustment reflects a positive outlook on the stock’s performance in the market.
The analyst retained a "Buy" rating for Cormedix (CRMD, Financial), indicating continued confidence in the company’s prospects. The consistent "Buy" rating suggests that Needham sees potential growth and value in Cormedix's operations and future ventures.
Investors and stakeholders in Cormedix (CRMD, Financial) will be keeping an eye on how this increased price target influences market performance and trading activities. With the adjustment, Cormedix aims to align its strategies with the anticipated market demands to achieve the updated valuation.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Cormedix Inc (CRMD, Financial) is $16.83 with a high estimate of $20.00 and a low estimate of $13.00. The average target implies an upside of 50.84% from the current price of $11.16. More detailed estimate data can be found on the Cormedix Inc (CRMD) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, Cormedix Inc's (CRMD, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Cormedix Inc (CRMD, Financial) in one year is $1809.38, suggesting a upside of 16113.08% from the current price of $11.16. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Cormedix Inc (CRMD) Summary page.
